Table 2 Grade 3 and 4 adverse events occurring during the six cycles of R2-CHOP

From: Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma

Grade 5 mg, n=3 10 mg, n=3 15 mg, n=3 20 mg, n=6 25 mg, n=12 All, n=27
  3 4 3 4 3 4 3 4 3 4 3 4
Anemia 0 0 0 0 0 0 2 0 2 0 4 0
Thrombocytopenia 1 0 0 0 0 0 2 0 4 1 7 1
Neutropenia 1 0 1 1 1 1 0 3 2 6 5 11
Febrile neutropenia 1 0 0 0 0 0 0 1 0 0 2 0
Infection 0 0 0 0 0 0 0 0 0 1 0 1
Thromboembolism 0 0 0 0 0 0 0 1 1 0 1 1
AST/ALT elevated 0 0 0 0 1 0 1 0 1 0 2 0
Pulmonary 0 0 0 0 0 0 1 0 0 0 1 0
Other 0 0 1 0 0 1 2 0 2 0 5 1
  1. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
  2. Other grade 3 events were: 1 hypokaliemia, 1 lymphopenia, 1 bleeding related to catheter desinsertion, 1 hyponatremia, 1 hyperglycemia. Other grade 4; 1 hyperuricemia.